[go: up one dir, main page]

AR106449A2 - Formulación inyectable de aripiprazol estéril de liberación controlada la cual, después de la inyección, libera aripiprazol, una formulación de aripiprazol estéril de liberación controlada secada por congelamiento, y un método para su preparación - Google Patents

Formulación inyectable de aripiprazol estéril de liberación controlada la cual, después de la inyección, libera aripiprazol, una formulación de aripiprazol estéril de liberación controlada secada por congelamiento, y un método para su preparación

Info

Publication number
AR106449A2
AR106449A2 ARP160103230A ARP160103230A AR106449A2 AR 106449 A2 AR106449 A2 AR 106449A2 AR P160103230 A ARP160103230 A AR P160103230A AR P160103230 A ARP160103230 A AR P160103230A AR 106449 A2 AR106449 A2 AR 106449A2
Authority
AR
Argentina
Prior art keywords
sterile
formulation
aripiprazol
aripiprazole
injection
Prior art date
Application number
ARP160103230A
Other languages
English (en)
Inventor
H Naringrekar Vijay
Nerurkar Manoj
Matsuda Takakuni
W Kostanski Janusz
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34549292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR106449(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR106449A2 publication Critical patent/AR106449A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación inyectable estéril de aripiprazol, de liberación controlada la cual, después de la inyección, libera aripiprazol, que comprende: (a) aripipriopazol con un tamaño de partícula medio de 1 a 10 mm, (b) un vehículo para este, y (c) agua para inyección, en donde la formulación está en la forma de una suspensión estéril homogénea. Una formulación de aripiprazol estéril de liberación controlada secada por congelamiento, y un método para su preparación. Reivindicación 1: Una formulación inyectable estéril de aripiprazol, de liberación controlada la cual, después de la inyección, libera aripiprazol, caracterizada porque comprende: (a) aripipriopazol con un tamaño de partícula medio de 1 a 10 mm, (b) un vehículo para este, y (c) agua para inyección, en donde la formulación esté en la forma de una suspensión estéril homogénea. Reivindicación 22: Un método para preparar la formulación secada por congelamiento estéril de conformidad con la reivindicación 16, caracterizado porque comprende los pasos de: (a) preparar aripiprazol en volumen estéril, que tiene una distribución de tamaño de partícula deseada, (b) preparar un vehículo estéril para el aripiprazol en volumen estéril, (c) combinar dicho aripiprazol estéril y dicho vehículo estéril para formar una suspensión primaria estéril, (d) reducir el tamaño de partícula promedio de aripiprazol en dicha suspensión primaria estéril dentro del rango de 1 a 10 mm para formar una suspensión estéril final, y (e) secar por congelamiento dicha suspensión final estéril para formar la formulación secado por congelamiento.
ARP160103230A 2003-10-23 2016-10-21 Formulación inyectable de aripiprazol estéril de liberación controlada la cual, después de la inyección, libera aripiprazol, una formulación de aripiprazol estéril de liberación controlada secada por congelamiento, y un método para su preparación AR106449A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51361803P 2003-10-23 2003-10-23

Publications (1)

Publication Number Publication Date
AR106449A2 true AR106449A2 (es) 2018-01-17

Family

ID=34549292

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP040103849A AR046141A1 (es) 2003-10-23 2004-10-22 Formulacion de aripripazol inyectable, esteril, de liberacion controlada y metodo
ARP160103230A AR106449A2 (es) 2003-10-23 2016-10-21 Formulación inyectable de aripiprazol estéril de liberación controlada la cual, después de la inyección, libera aripiprazol, una formulación de aripiprazol estéril de liberación controlada secada por congelamiento, y un método para su preparación

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP040103849A AR046141A1 (es) 2003-10-23 2004-10-22 Formulacion de aripripazol inyectable, esteril, de liberacion controlada y metodo

Country Status (32)

Country Link
US (12) US7807680B2 (es)
EP (1) EP1675573B2 (es)
JP (2) JP4836797B2 (es)
KR (1) KR100931784B1 (es)
CN (1) CN1870980B (es)
AR (2) AR046141A1 (es)
AT (1) ATE411797T2 (es)
AU (1) AU2004285448C1 (es)
BR (1) BRPI0415531B8 (es)
CA (1) CA2543242C (es)
CO (1) CO5690539A2 (es)
CY (2) CY1109040T1 (es)
DE (1) DE602004017342D1 (es)
DK (1) DK1675573T4 (es)
EC (2) ECSP066512A (es)
ES (1) ES2315721T5 (es)
FR (1) FR14C0039I1 (es)
GE (1) GEP20115205B (es)
IL (1) IL175072A (es)
LU (1) LU92427I2 (es)
MX (1) MXPA06004489A (es)
MY (1) MY146093A (es)
NO (2) NO334919B1 (es)
NZ (1) NZ546063A (es)
PE (1) PE20050811A1 (es)
PL (1) PL1675573T4 (es)
PT (1) PT1675573E (es)
SI (1) SI1675573T2 (es)
TW (2) TWI383810B (es)
UA (1) UA82561C2 (es)
WO (1) WO2005041937A2 (es)
ZA (1) ZA200602347B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
CA2543242C (en) 2003-10-23 2015-04-14 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof
EP1812397A1 (en) * 2004-11-18 2007-08-01 Synthon B.V. Process of making crystalline aripiprazole
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP1808164B2 (en) 2006-01-05 2018-07-04 Teva Pharmaceutical Industries Ltd Wet granulation method for preparing pharmaceutical compositions of aripiprazole
WO2007081367A1 (en) * 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Dry formulations of aripiprazole
TR200604349A2 (tr) * 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
ES2529746T3 (es) * 2007-06-25 2015-02-25 Otsuka Pharmaceutical Co., Ltd. Microesferas con una estructura de núcleo/cáscara
PT2170279T (pt) * 2007-07-31 2018-04-06 Otsuka Pharma Co Ltd Métodos para produção de suspensão de aripiprazole e formulação liofilizada
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
KR101125210B1 (ko) * 2009-09-11 2012-03-19 주식회사 대웅제약 아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
CN103284968B (zh) * 2010-04-13 2015-11-18 齐鲁制药有限公司 一种阿立哌唑组合物微晶的口腔崩解片及其制备方法
IL206739A (en) * 2010-06-30 2016-06-30 David Segal An injectable drug containing silitol as an active substance
PH12012502076A1 (en) 2010-08-24 2013-02-04 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
US9757374B2 (en) * 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
WO2012058091A2 (en) * 2010-10-28 2012-05-03 Alpha To Omega Pharmaceutical Consultants, Inc. Aripiprazole compositions and methods for its transdermal delivery
AR083884A1 (es) 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
CN102525915B (zh) * 2010-12-14 2016-09-28 江苏豪森药业集团有限公司 一种持续释放的注射制剂及其制备方法和用途
CA2910333C (en) * 2011-01-24 2017-03-07 Otsuka Pharmaceutical Co., Ltd. Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
EP3156056B1 (en) 2011-03-18 2023-12-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
US9241876B2 (en) * 2011-06-27 2016-01-26 Shanghai Zhongxi Pharmaceutical Corporation Aripiprazole medicament formulation and preparation method therefor
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
CA2867137C (en) 2012-03-19 2020-12-08 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
CA2867123C (en) 2012-03-19 2021-02-16 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
JP6471089B2 (ja) * 2012-03-19 2019-02-13 アルカームス ファーマ アイルランド リミテッド 脂肪酸エステルを含む医薬組成物
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
PL2888286T3 (pl) * 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL2888593T3 (pl) * 2012-08-21 2019-02-28 Janssen Pharmaceutica Nv Przeciwciała przeciwko rysperydonowi i ich zastosowanie
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用
CN108640996A (zh) 2012-08-21 2018-10-12 詹森药业有限公司 帕潘立酮的抗体及其用途
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
KR20170052704A (ko) * 2013-04-30 2017-05-12 오쓰까 세이야꾸 가부시키가이샤 아리피프라졸을 포함하는 경구 고형 제제 및 아리피프라졸을 포함하는 경구 고형 제제의 제조방법
AR096131A1 (es) 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
JP6524110B2 (ja) * 2014-03-20 2019-06-05 アルカームス ファーマ アイルランド リミテッド 注射速度が増大したアリピプラゾール調合物
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
HRP20211271T1 (hr) * 2014-08-18 2022-01-07 Alkermes Pharma Ireland Limited Pripravci aripiprazolskog predlijeka
MA40480B1 (fr) * 2014-08-25 2021-08-31 Alkermes Pharma Ireland Ltd Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
TWI584823B (zh) * 2015-08-31 2017-06-01 諾瑞特國際藥業股份有限公司 具有延長的保存期限的阿立哌唑可注射懸浮液製劑
CN106474058B (zh) * 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
JP6504019B2 (ja) * 2015-10-27 2019-04-24 豊田合成株式会社 発光装置
MA44067A (fr) 2015-12-17 2018-10-24 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
CN105663057A (zh) * 2015-12-30 2016-06-15 中国药科大学 阿立哌唑长效混悬剂及其制备方法
US20190160002A1 (en) * 2016-07-28 2019-05-30 Mylan Laboratories Limited Process for preparing sterile aripiprazole formulation
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
KR102486564B1 (ko) * 2019-08-23 2023-01-19 주식회사 대웅테라퓨틱스 니클로사마이드 지연방출 조성물 및 이의 항바이러스 용도
WO2021140424A1 (en) * 2020-01-06 2021-07-15 Shilpa Medicare Limited Fingolimod extended release injectable suspension
WO2021199076A1 (en) 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
MX2022012353A (es) * 2020-04-01 2022-10-31 Otsuka Pharma Co Ltd Metodos para el inicio de la dosis de los tratamientos con aripiprazol.
KR102606504B1 (ko) * 2020-04-10 2023-11-29 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
WO2021233402A1 (zh) * 2020-05-21 2021-11-25 江苏先声药业有限公司 一种含依匹哌唑药物组合物及其制备方法
KR102785446B1 (ko) * 2020-09-09 2025-03-25 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 항인플루엔자 바이러스용 조성물
CN112656761B (zh) * 2020-12-30 2023-09-08 河南合智医药科技有限公司 一种低刺激性阿立哌唑前药的油溶缓释注射制剂及其制备方法
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115554253B (zh) * 2022-10-14 2024-03-29 浙江圣兆药物科技股份有限公司 一种平稳释药的注射用阿立哌唑冻干制剂及其制备方法
GR1010656B (el) * 2023-03-23 2024-03-21 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει εναν ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
GR1010624B (el) * 2023-03-23 2024-01-30 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει αριπιπραζολη και μεθοδος για την παρασκευη αυτου
WO2024225441A1 (en) 2023-04-26 2024-10-31 Otsuka Pharmaceutical Co., Ltd. Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209551A (en) 1922-11-20 1924-01-17 William Mortimer Melmore Improvements in or relating to petrol and other cans
US4038389A (en) 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
CA1209477A (en) 1981-03-26 1986-08-12 Bruce E. Haeger Composition of matter comprising a lyophilized preparation of a penicillin derivative
JPS5832899A (ja) 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
US4352811A (en) 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
IL68549A (en) * 1983-05-03 1988-05-31 Kit Medidont Ltd Method and instrument for measuring moisture
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JPH03212852A (ja) 1990-01-18 1991-09-18 Hitachi Electron Eng Co Ltd 記録媒体カートリッジ搬送装置における送り機構
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
JP3282731B2 (ja) 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
IT1244880B (it) 1990-12-11 1994-09-12 Torre A Farmaceutici Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
US6193983B1 (en) 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
SK282231B6 (sk) 1993-11-19 2001-12-03 Janssen Pharmaceutica N. V. Farmaceutický prostriedok na liečenie psychotických porúch
DE69530196T2 (de) 1994-06-02 2003-11-20 Elan Drug Delivery Ltd Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
RU2082401C1 (ru) 1994-08-18 1997-06-27 Фармацевтическое акционерное общество "Ферейн" Способ получения лекарственной формы комбинированного препарата
US6165442A (en) 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
ATE252891T1 (de) 1996-08-26 2003-11-15 Transgene Sa Kationische lipid-nukleinsäure komplexe
US6297231B1 (en) 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO2000006124A2 (en) 1998-07-30 2000-02-10 Point Biomedical Corporation A novel excipient for the lyophilization of aqueous suspensions of microparticles
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
CA2382921A1 (en) 1999-12-09 2001-06-14 Syngenta Participations Ag Pyrazolecarboxamide and pyrazolethioamide as fungicide
JP2001187735A (ja) * 2000-01-05 2001-07-10 Towa Yakuhin Kk 安定なニコランジル含有粉末の製造法
US6559128B1 (en) 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
RU2169574C1 (ru) 2000-01-27 2001-06-27 Кобатов Алексей Иванович Способ получения биопрепарата и сухой биопрепарат
AU2001233180A1 (en) 2000-02-10 2001-08-20 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
JP2003528850A (ja) 2000-03-27 2003-09-30 ザ・スクリプス・リサーチ・インステイチユート 血管形成および腫瘍成長の阻害
EP1187602A4 (en) 2000-04-18 2004-09-15 Peptron Inc SUSTAINABLE RELEASE INJECTABLE PHARMACEUTICAL COMPOSITION AND METHODS OF PREPARING THE SAME
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002241284A (ja) * 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US6884768B2 (en) 2001-06-14 2005-04-26 Otsuka Pharmaceutical Co., Ltd. Medicinal compositions
DK1429734T3 (da) 2001-09-21 2008-05-13 Egalet As Faste dispersioner af carvedilol til kontrolleret afgivelse
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
MY138669A (en) * 2001-09-25 2009-07-31 Otsuka Pharma Co Ltd Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
ITMI20020808A1 (it) 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
CN100335047C (zh) * 2002-08-20 2007-09-05 布里斯托尔-迈尔斯斯奎布公司 阿立哌唑复合制剂和方法
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
CA2543242C (en) 2003-10-23 2015-04-14 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof
EP1677738A2 (en) 2003-10-31 2006-07-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents

Also Published As

Publication number Publication date
PL1675573T5 (pl) 2012-10-31
NO20062319L (no) 2006-07-21
SI1675573T1 (sl) 2009-02-28
CO5690539A2 (es) 2006-10-31
WO2005041937A3 (en) 2006-04-06
US20050148597A1 (en) 2005-07-07
DE602004017342D1 (de) 2008-12-04
KR20060118450A (ko) 2006-11-23
TWI421101B (zh) 2014-01-01
US9763935B2 (en) 2017-09-19
ECSP066512A (es) 2006-10-10
DK1675573T4 (da) 2012-08-06
CY2014021I2 (el) 2017-03-15
UA82561C2 (uk) 2008-04-25
US20080112985A1 (en) 2008-05-15
AR046141A1 (es) 2005-11-23
KR100931784B1 (ko) 2009-12-14
LU92427I2 (fr) 2014-06-11
JP2007509148A (ja) 2007-04-12
TW200524638A (en) 2005-08-01
NZ546063A (en) 2009-05-31
US20140018369A1 (en) 2014-01-16
NO334919B1 (no) 2014-07-14
PL1675573T4 (pl) 2016-04-29
ES2315721T5 (es) 2012-08-24
EP1675573A2 (en) 2006-07-05
US20120100190A1 (en) 2012-04-26
ES2315721T3 (es) 2009-04-01
RU2342927C2 (ru) 2009-01-10
AU2004285448C1 (en) 2021-08-19
CY1109040T1 (el) 2014-07-02
CA2543242C (en) 2015-04-14
ES2315721T9 (es) 2015-11-05
US20080112986A1 (en) 2008-05-15
BRPI0415531B8 (pt) 2021-05-25
RU2006109111A (ru) 2007-09-27
US8722679B2 (en) 2014-05-13
US20200061057A1 (en) 2020-02-27
PL1675573T3 (pl) 2009-04-30
EP1675573B2 (en) 2012-06-13
PT1675573E (pt) 2008-12-30
AU2004285448A1 (en) 2005-05-12
FR14C0039I1 (fr) 2014-06-27
DK1675573T3 (da) 2009-01-05
CY2014021I1 (el) 2014-07-02
US8030313B2 (en) 2011-10-04
GEP20115205B (en) 2011-04-26
US20240261280A1 (en) 2024-08-08
JP4836797B2 (ja) 2011-12-14
ATE411797T2 (de) 2008-11-15
NO2014027I1 (no) 2014-11-10
HK1095266A1 (zh) 2007-05-04
MXPA06004489A (es) 2006-06-20
PE20050811A1 (es) 2005-09-25
WO2005041937A2 (en) 2005-05-12
CA2543242A1 (en) 2005-05-12
US7807680B2 (en) 2010-10-05
MY146093A (en) 2012-06-29
CN1870980B (zh) 2010-06-23
BRPI0415531A (pt) 2006-12-26
NO2014027I2 (no) 2014-10-27
CN1870980A (zh) 2006-11-29
US20080107745A1 (en) 2008-05-08
US20210338663A1 (en) 2021-11-04
IL175072A (en) 2015-06-30
JP2011102316A (ja) 2011-05-26
ZA200602347B (en) 2007-09-26
US20170348308A1 (en) 2017-12-07
JP5372032B2 (ja) 2013-12-18
LU92427I9 (es) 2019-01-17
US20150024056A1 (en) 2015-01-22
BRPI0415531B1 (pt) 2019-07-30
TWI383810B (zh) 2013-02-01
ECSP12006512A (es) 2012-02-29
US8952013B2 (en) 2015-02-10
IL175072A0 (en) 2006-08-20
AU2004285448B2 (en) 2009-06-11
SI1675573T2 (sl) 2012-08-31
TW201204413A (en) 2012-02-01
US20080221121A1 (en) 2008-09-11
EP1675573B1 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
AR106449A2 (es) Formulación inyectable de aripiprazol estéril de liberación controlada la cual, después de la inyección, libera aripiprazol, una formulación de aripiprazol estéril de liberación controlada secada por congelamiento, y un método para su preparación
ES2525320T3 (es) Composiciones de calentamiento y sistemas para su descarga
ES2565308T3 (es) Dispositivo poligonal generador de aerosol
BR112012016021A2 (pt) formulações estáveis para liofilização de partículas terapêuticas
CL2012000730A1 (es) Barra articulada en tres planos para el uso en implantes dentarios, la cual esta formada por un conjunto de brazos retractiles, en que un brazo es dotado de una extension que se encaja de forma deslizante en el brazo complementar, presentan un encaje concavo y/u otro encaje esferico.
ECSP13012647A (es) Dispersiones sólidas extruidas por fusión que contienen un agente inductor de apoptosis
AR087664A1 (es) Mejoras relacionadas con composiciones para el tratamiento de superficies que comprenden agentes de beneficio direccionados
ES2478820T3 (es) Tratamiento de degeneración macular
AR071239A1 (es) Microesferas que tienen una estructura de nucleo / recubrimiento que comprenden aripiprazol y uso
UY33437A (es) Dispersiones solidas que contienen inhibidores de quinasas
PE20142442A1 (es) Formulacion de farmaco de liberacion retardada
BRPI0707044B8 (pt) comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais
TN2011000261A1 (en) Octreotide depot formulation with constantly high exposure levels
ES2629309T3 (es) Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora
BR112012001240A2 (pt) dispersão polimérica aquosa, processo para preparar uma dispersão polimérica aquosa, agente de revestimento na forma de uma composição aquosa, e, uso da dispersão polimérica aquosa
BR112015001640A2 (pt) formulações e métodos de produção de formulações para uso em evacuação colônica
CO2019003876A2 (es) Formulación farmacéutica parenteral que contiene ácido carglúmico
AR052233A1 (es) Formulacion liofilizada, estabilizada, para derivados de la cefalosporina
MX2016003562A (es) Dispositivo de anclaje.
MX391574B (es) Partículas coloidales para su uso en medicina.
MY159739A (en) Freeze-dried preparation of tetrodotoxin and the producing method thereof
AR032036A1 (es) Tratamiento de tumores inoperables por medio de inyeccion estereotactica de microesferas
BR112012013823A2 (pt) "formulação farmacêutica parenteral em suspensão, de liberação prolongada"
DOP2011000030A (es) Combinacion coccidicida para uso veterinario
DOP2006000184A (es) Forma farmacéutica con liberación sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph

Legal Events

Date Code Title Description
FC Refusal